{
  "guideline": {
    "id": "PA166182842",
    "name": "Annotation of DPWG Guideline for warfarin and CYP2C9",
    "source": "DPWG",
    "version": 5,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182842",
    "relatedChemicals": [
      {
        "id": "PA451906",
        "name": "warfarin",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA126",
        "name": "cytochrome P450 family 2 subfamily C member 9",
        "symbol": "CYP2C9"
      }
    ],
    "recommendation": true,
    "guidelineGenes": [
      {
        "alleles": [
          {
            "id": 1451445367,
            "_label": "*1",
            "function": {
              "term": "Normal function (CYP2C9*1)",
              "termId": "alleleFunction:1451444660"
            }
          },
          {
            "id": 1451445368,
            "_label": "*2",
            "function": {
              "term": "Decreased function (CYP2C9*2)",
              "termId": "alleleFunction:1451444630"
            }
          },
          {
            "id": 1451445369,
            "_label": "*3",
            "function": {
              "term": "Decreased function (CYP2C9*3)",
              "termId": "alleleFunction:1451444680"
            }
          },
          {
            "id": 1451445361,
            "_label": "*4",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445362,
            "_label": "*5",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445363,
            "_label": "*6",
            "function": {
              "term": "No function",
              "termId": "haplotypeTags:1445558515"
            }
          },
          {
            "id": 1451445364,
            "_label": "*8",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445365,
            "_label": "*11",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445366,
            "_label": "*12",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          },
          {
            "id": 1451445370,
            "_label": "*13",
            "function": {
              "term": "Decreased function",
              "termId": "haplotypeTags:1445558331"
            }
          }
        ],
        "gene": {
          "chr": {
            "id": "PA504",
            "name": "chr10",
            "symbol": null
          },
          "strand": "plus",
          "id": "PA126",
          "name": "cytochrome P450 family 2 subfamily C member 9",
          "symbol": "CYP2C9"
        }
      }
    ]
  },
  "annotationGroups": [
    {
      "id": "PA166244022",
      "name": "*1/*2",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451445375,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451445377,
        "html": "<p>NO action is required for this gene-drug interaction.</p>\n"
      },
      "implications": {
        "id": 1451445374,
        "html": "<p>Genetic variation may lead to a decrease in the required maintenance dose. However, there is insufficient evidence that this causes problems when therapy is initiated as usual.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244027",
      "name": "Normal Metabolizer",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "No",
        "termId": "rxChange:1448602495"
      },
      "genePhenotypes": [
        "CYP2C9:Normal function (CYP2C9*1)/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451445438,
        "html": "<p>Normal Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451445439,
        "html": "<p>The guideline does not provide a recommendation for warfarin in normal metabolizers.</p>\n"
      },
      "implications": {
        "id": 1451445437,
        "html": "<p>The guideline does not provide a description of the impact of a normal metabolizer phenotype on warfarin.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244021",
      "name": "Intermediate Metabolizer",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function/Normal function (CYP2C9*1)",
        "CYP2C9:No function/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451838338,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838339,
        "html": "<ol>\n<li>use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *1/*2 or *1/*3 is present. See <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838337,
        "html": "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244023",
      "name": "*1/*3",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*3)/Normal function (CYP2C9*1)"
      ],
      "metabolizerStatus": {
        "id": 1451838341,
        "html": "<p>Intermediate Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838343,
        "html": "<ol>\n<li>use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838340,
        "html": "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244024",
      "name": "*2/*2",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/Decreased function (CYP2C9*2)"
      ],
      "metabolizerStatus": {
        "id": 1451838345,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838347,
        "html": "<ol>\n<li>use 65% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838344,
        "html": "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244025",
      "name": "*2/*3",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/Decreased function (CYP2C9*3)"
      ],
      "metabolizerStatus": {
        "id": 1451838349,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838351,
        "html": "<ol>\n<li>use 45% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838348,
        "html": "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244026",
      "name": "*3/*3",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*3)/Decreased function (CYP2C9*3)"
      ],
      "metabolizerStatus": {
        "id": 1451838353,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838355,
        "html": "<ol>\n<li>use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm, as used in EU-PACT: see <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a>. From day 6 on the standard algorithm without genotype information can be used to calculate the dose.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838352,
        "html": "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n"
      },
      "activityScore": null
    },
    {
      "id": "PA166244041",
      "name": "Poor Metabolizer",
      "strength": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "rxChangeStatus": {
        "term": "Yes",
        "termId": "rxChange:1448602497"
      },
      "genePhenotypes": [
        "CYP2C9:Decreased function (CYP2C9*2)/No function",
        "CYP2C9:Decreased function (CYP2C9*3)/No function",
        "CYP2C9:Decreased function/Decreased function",
        "CYP2C9:Decreased function/Decreased function (CYP2C9*2)",
        "CYP2C9:Decreased function/Decreased function (CYP2C9*3)",
        "CYP2C9:Decreased function/No function",
        "CYP2C9:No function/No function"
      ],
      "metabolizerStatus": {
        "id": 1451838357,
        "html": "<p>Poor Metabolizer</p>\n"
      },
      "recommendation": {
        "id": 1451838358,
        "html": "<ol>\n<li>use 20% of the standard initial dose. The genotype-specific initial dose and maintenance dose can be calculated using an algorithm. Algorithms for Caucasian patients usually contain only the *2 and *3 allele. If the activity of the reduced-activity alleles is comparable to the activity of *2 or *3, then the algorithm can be completed as if *2 or *3 is present. See <a rel=\"noopener noreferrer\" href=\"https://www.knmp.nl/producten/gebruiksrecht-g-standaard/medicatiebewaking-g-standaard/background-information-pharmacogenetics\" target=\"_blank\">Algorithms coumarins</a> for Excel files containing calculation modules for oral and equivalent intravenous doses. From day 6 on the standard algorithm without genotype information can be used to calculate the dose. Modified dose algorithms have been developed for patients of African or (East) Asian heritage.</li>\n</ol>\n"
      },
      "implications": {
        "id": 1451838356,
        "html": "<p>This gene variation reduces the conversion of warfarin to inactive metabolites. This can increase the risk of bleeding.</p>\n"
      },
      "activityScore": null
    }
  ],
  "citations": [],
  "version": "2023-01-05-00-25"
}